Reduced resistance and exacerbated lung inflammation in <i>ccr2</i>^-/- mice with <i>C</i>. <i>muridarum</i> respiratory infection. by Shuaini Yang (20670608)

Subjects:

Root mean square fluctuations of the wild-type (green line) and mutant (H5Q) (purple line) proteins of AKR1C3 (complexed with the ligand NADPH). by Md. Akeruzzaman Shaon (21511929)

Subjects:

Changes in connectivity of the mPFC among responders and non-responders. by Karel Joineau (21799908)

Subjects:

Data supporting this article. by Karel Joineau (21799908)

Subjects:

CONSORT diagram showing the flow of participants through each stage of the DOREPAR randomized trial for the main outcome (change of VAS). by Karel Joineau (21799908)

Subjects:

Demographic and clinical data at baseline. by Karel Joineau (21799908)

Subjects:

Changes in clinical variables. by Karel Joineau (21799908)

Subjects:

Change of functional connectivity in the SMN after intervention. by Karel Joineau (21799908)

Subjects:

Connectivity between the left nucleus accumbens and two clusters. by Karel Joineau (21799908)

Subjects:

Design of the protocol. by Karel Joineau (21799908)

Subjects:

Schema of the reflexology circuit and the stimulated reflex zones. a. by Karel Joineau (21799908)

Subjects:

Trends of incident opioid users, L-TOT users, and L-TOT discontinuers between 2009 and 2013. by Qian Cai (112039)

Subjects:

The yearly numerator, denominator and rate of incident opioid users, L-TOT users and L-TOT discontinuers from 2009 to 2019. by Qian Cai (112039)

Subjects:

Incidence rate ratios of negative binominal regression models for yearly rates of incident opioid users, L-TOT users and L-TOT discontinuers during 2009–2013 and 2015–2019. by Qian Cai (112039)

Subjects:

Demographic, comorbidity, concurrent drug, and opioid characteristics, among L-TOT users and L-TOT discontinuers between 2009–2019. by Qian Cai (112039)

Subjects:

Kaplan-Meier curves and time-dependent Cox regression for outcome of mortality. by Jennifer M. Kwan (3350321)

Subjects:

Cox regression models for adverse cardiovascular events (ACE) and individual components of ACE. by Jennifer M. Kwan (3350321)

Subjects:

Adverse cardiovascular events by immune checkpoint inhibitor. by Jennifer M. Kwan (3350321)

Subjects:

Baseline demographics and comorbidities by presence of post-treatment adverse cardiovascular events. by Jennifer M. Kwan (3350321)

Subjects:

Minimal dataset. by Jennifer M. Kwan (3350321)

Subjects: